Late Breaking Abstract - COPD exacerbation benefits relative to pneumonia risk with budesonide/glycopyrronium/formoterol metered dose inhaler: analyses from ETHOS
K. Rabe (Grosshansdorf, Germany), F. Martinez (New York, NY, United States of America), G. Ferguson (Farmington Hills, MI, United States of America), D. Singh (Manchester, United Kingdom), J. Wedzicha (London, United Kingdom), M. Jenkins (Cambridge, United Kingdom), M. Aurivillius (Gothenburg, Sweden), C. Reisner (Morristown, NJ, United States of America), P. Dorinsky (Durham, NC, United States of America)
Source: Virtual Congress 2020 – Advances in pharmacological treatment of COPD
Session: Advances in pharmacological treatment of COPD
Session type: Oral Presentation
Number: 5230
Disease area: Airway diseases
Rating:
You must login to grade this presentation.
Share or cite this content
Citations should be made in the following way:
K. Rabe (Grosshansdorf, Germany), F. Martinez (New York, NY, United States of America), G. Ferguson (Farmington Hills, MI, United States of America), D. Singh (Manchester, United Kingdom), J. Wedzicha (London, United Kingdom), M. Jenkins (Cambridge, United Kingdom), M. Aurivillius (Gothenburg, Sweden), C. Reisner (Morristown, NJ, United States of America), P. Dorinsky (Durham, NC, United States of America). Late Breaking Abstract - COPD exacerbation benefits relative to pneumonia risk with budesonide/glycopyrronium/formoterol metered dose inhaler: analyses from ETHOS. 5230
You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
Related content which might interest you:
Related content which might interest you: